

Biopharmaceutical Tubing Market 2024–2031: USD 3,580M to USD 6,674M at 8.3% CAGR Growth | Report by DataM Intelligence

Biopharmaceutical tubing market grows at 8.3% CAGR, fueled by vaccines, mAbs, and cell & gene therapy demand.

AUSTIN, TX, UNITED STATES, September 4, 2025 /EINPresswire.com/ -- According to DataM Intelligence, the [Biopharmaceutical Tubing Market](#) size reached USD 3,580.4 million in 2022 and is projected to witness lucrative growth, reaching USD 6,674.2 million by 2031, growing at a CAGR of 8.3% during the forecast period (2024–2031). Single-use tubing systems are leading the demand due to their

operational safety, flexibility, and ability to minimize cross-contamination risks. Geographically, North America dominates the global market, driven by advanced biomanufacturing capabilities, strong investment in biologics, and stringent regulatory oversight. Meanwhile, the Asia-Pacific region is expected to emerge as the fastest-growing market, owing to expanding biologics manufacturing hubs in China and India, coupled with significant government incentives.

“

Flexible single-use systems, regulatory compliance, and biologics growth collectively drive the biopharmaceutical tubing market from USD 3,580.4 Million to USD 6,674.2 Million.”

DataM Intelligence

The biopharmaceutical tubing market has become an integral part of the global life sciences sector, as sterile fluid transfer systems are indispensable in the manufacturing and delivery of biologics, vaccines, and advanced therapies. These high-purity tubes are used in bioreactors, chromatography systems, filtration units, and filling operations, ensuring contamination-free drug development. With the rapid rise of biologics, biosimilars,

and personalized medicine, demand for advanced tubing systems has soared. Manufacturers are increasingly prioritizing high-performance, sterilizable, and regulatory-compliant tubing



materials to meet the evolving needs of drug makers.

□□□ □ □□□□□□ □□□ □□□□□□□□ □□ □□□ □□□□□□ (□□□ □□□□□□□□□□ □□□□□ □□ □□□ □ □□□□□ □□□□□□□□): <https://www.datamintelligence.com/download-sample/biopharmaceutical-tubing-market>

Key Highlights from the Report

- The global biopharmaceutical tubing market was valued at USD 3,580.4 million in 2022 and is set to grow to USD 6,674.2 million by 2031.
- Single-use tubing systems dominate the market due to their sterility, ease of operation, and growing use in biopharma production.
- Silicone and thermoplastic elastomers (TPEs) are the most widely used tubing materials for their biocompatibility and sterilization compatibility.
- North America leads the market share, supported by advanced infrastructure and strong biologics pipeline.
- Asia-Pacific is projected to post the highest CAGR, driven by biologics outsourcing and local manufacturing growth.
- Increasing focus on eco-friendly tubing materials and sensor-enabled smart tubing is reshaping the future of the industry.

Market Segmentation

The biopharmaceutical tubing market is segmented based on product type, material, end-user, and application, providing a comprehensive view of the industry landscape.

By Product Type, the market is primarily divided into single-use tubing and multi-use tubing. Single-use tubing has emerged as the dominant segment due to its convenience, sterility, and ability to minimize contamination risks. It is especially preferred in flexible manufacturing facilities and contract manufacturing organizations where multiple products are processed. Multi-use tubing, on the other hand, is widely used in high-volume, repetitive processes where in-house sterilization facilities are available. Although less flexible, multi-use tubing remains relevant in cost-sensitive applications due to its long-term usability.

By Material, biopharmaceutical tubing is manufactured from a variety of polymers that cater to specific processing needs. Silicone remains the most widely adopted material for its biocompatibility, flexibility, and resistance to extreme temperatures, making it suitable for critical drug transfer processes. Thermoplastic elastomers (TPEs) are increasingly favored due to their cost-effectiveness, weldability, and sterilization compatibility. Specialized materials such as fluoropolymers (PTFE, FEP, PFA) are used in applications requiring high chemical resistance, while PVC tubing finds niche applications where cost constraints are significant, though its use is declining due to environmental and regulatory concerns.

By End-User, the market serves a broad range of customers. Biopharmaceutical manufacturers represent the largest segment, as they require reliable tubing for large-scale biologics, vaccine, and biosimilar production. Contract Manufacturing Organizations (CMOs) are adopting single-use tubing systems to efficiently manage multi-client operations with varying process requirements. Additionally, research and development centers and academic institutes drive demand for small-scale, high-purity tubing solutions used in early-stage drug development and process optimization studies.

By Application, biopharmaceutical tubing is extensively used across bioreactor systems, filtration and chromatography units, media and buffer transfer, drug filling and packaging lines, and cell and gene therapy processes. Bioreactor and filtration applications dominate due to the critical need for contamination-free fluid transfer and precise flow control. Media and buffer transfer applications are growing steadily, driven by the increasing adoption of single-use systems and the rise of complex biologics manufacturing. The surge in cell and gene therapy pipelines is also creating new opportunities for specialized tubing systems that support sensitive and high-value therapies.

Looking For A Detailed Full Report? Get it here: <https://www.datamintelligence.com/buy-now-page?report=biopharmaceutical-tubing-market>

Regional Insights

The biopharmaceutical tubing market demonstrates diverse regional growth patterns:

North America: Holds the largest share, driven by the U.S. biopharmaceutical ecosystem. Strong FDA oversight, large-scale biologics production, and a concentration of leading tubing suppliers position the region as a market leader.

Europe: Germany, Switzerland, and the UK dominate due to significant R&D investment, established pharma companies, and the rising demand for biosimilars. Stringent EMA guidelines ensure high compliance rates, boosting validated tubing adoption.

Asia-Pacific: The fastest-growing region. China and India are heavily investing in biologics and biosimilar production facilities. Outsourcing and government-backed initiatives accelerate tubing demand.

Latin America and Middle East & Africa: These regions are still emerging but show promise, especially with rising local biosimilar production in Brazil, Saudi Arabia, and South Africa. Growing healthcare expenditure is expected to expand tubing adoption gradually.

Market Dynamics

Market Drivers

The rise in biologics and biosimilars production remains the strongest driver. Demand for sterile fluid handling solutions has grown alongside monoclonal antibody therapies, mRNA vaccines, and cell & gene therapies. Regulatory agencies are also enforcing stricter contamination controls, boosting the demand for validated, high-quality tubing. The growing preference for single-use systems further accelerates adoption due to their role in reducing cleaning costs and cross-contamination.

Market Restraints

High material and manufacturing costs remain a challenge, particularly for small-scale producers in emerging markets. In addition, the environmental burden of disposable plastics in single-use systems is drawing scrutiny. Supply chain disruptions, especially in medical-grade silicone and TPEs, can also restrict market growth.

Market Opportunities

Sustainability presents a major opportunity—companies are actively developing biodegradable or recyclable tubing solutions. The rise of smart tubing embedded with flow sensors and RFID tags provides scope for real-time process monitoring. Emerging markets in Asia-Pacific and Latin America, with expanding local manufacturing bases, offer new revenue streams for tubing providers.

Get Customization in the report as per your requirements:

<https://www.datamintelligence.com/customize/biopharmaceutical-tubing-market>

Reasons to Buy the Report

- In-depth market analysis with accurate growth forecasts through 2031.
- Detailed segmentation by product, material, application, and end-user.
- Comprehensive coverage of regional dynamics and emerging growth hubs.
- Competitive landscape insights with profiles of key players and their strategies.
- Strategic outlook for opportunities in sustainable and smart tubing technologies.

Frequently Asked Questions (FAQs)

- How big is the biopharmaceutical tubing market in 2022?
- What is the projected growth rate of the biopharmaceutical tubing market during 2024–2031?
- Which product segment dominates the biopharmaceutical tubing industry?
- Which region is expected to post the highest CAGR in the forecast period?
- Who are the key players operating in the global biopharmaceutical tubing market?

Company Insights

Key players operating in the biopharmaceutical tubing market include:

- Saint-Gobain Performance Plastics

- Parker Hannifin Corporation
- Watson-Marlow Fluid Technology Group
- Cole-Parmer (Antylia Scientific)
- Zeus Industrial Products
- Freelin-Wade (a subsidiary of the Trelleborg Group)

Recent Developments:

Saint-Gobain introduced a next-generation silicone tubing line with improved resistance to extractables and leachables, designed for biopharma applications.

Parker Hannifin announced the launch of sensor-enabled tubing systems integrated with real-time monitoring to enhance sterility assurance and process control.

Conclusion

The biopharmaceutical tubing market is positioned for sustained growth, supported by the surging demand for biologics, stringent regulatory compliance, and the shift towards single-use systems. With the market projected to grow from USD 3,580.4 million in 2022 to USD 6,674.2 million by 2031 at a CAGR of 8.3%, the industry is entering a phase of innovation and expansion. North America remains the dominant force, but Asia-Pacific is fast catching up with its booming biomanufacturing sector. As sustainability and digitalization transform the industry, biopharmaceutical tubing will continue to be a cornerstone of modern, contamination-free drug production.

Request for 2 Days FREE Trial Access: <https://www.datamintelligence.com/reports-subscription>

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Competitive Landscape

Sustainability Impact Analysis

KOL / Stakeholder Insights

Unmet Needs & Positioning, Pricing & Market Access Snapshots

Market Volatility & Emerging Risks Analysis

Quarterly Industry Report Updated

Live Market & Pricing Trends

Import-Export Data Monitoring

Have a look at our Subscription Dashboard: <https://www.youtube.com/watch?v=x5oEiqEqTWg>

Related Reports:

[Biopharmaceutical Fermentation Systems Market](#)

[Biopharmaceuticals Market](#)

Sai Kiran

DataM Intelligence 4market Research LLP

877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/846035083>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.